Natalizumab in progressive MS - Results of an open-label, phase 2A, proof-of-concept trial

Jeppe Romme Christensen, Rikke Ratzer, Lars Börnsen, Mark Lyksborg, Ellen Garde, Tim B. Dyrby, Hartwig R. Siebner, Per S. Sørensen, Finn Sellebjerg

Research output: Contribution to journalJournal articleResearchpeer-review

Fingerprint

Dive into the research topics of 'Natalizumab in progressive MS - Results of an open-label, phase 2A, proof-of-concept trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Neuroscience